Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Vaidyane Ayurved Laboratories's enterprise value is ₹1,483 Mil.
Vaidyane Ayurved Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹178 Mil. Therefore, Vaidyane Ayurved Laboratories's EV-to-EBITDA for today is 8.34.
The historical rank and industry rank for Vaidyane Ayurved Laboratories's EV-to-EBITDA or its related term are showing as below:
NSE:MADHAVBAUG'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.43 Med: 20.68 Max: 63.55
Current: 8.34
During the past 8 years, the highest EV-to-EBITDA of Vaidyane Ayurved Laboratories was 63.55. The lowest was 5.43. And the median was 20.68.
NSE:MADHAVBAUG's EV-to-EBITDA is ranked better than 69.83% of 726
companies
in the Drug Manufacturers industry
Industry Median: 13.55
vs NSE:MADHAVBAUG: 8.34
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vaidyane Ayurved Laboratories's PE Ratio (TTM) for today is calculated as:
Vaidyane Ayurved Laboratories's share price for today is ₹160.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vaidyane Ayurved Laboratories's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹8.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vaidyane Ayurved Laboratories's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vaidyane Ayurved Laboratories EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vaidyane Ayurved Laboratories's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Vaidyane Ayurved Laboratories's EV-to-EBITDA falls into.
Vaidyane Ayurved Laboratories's current Enterprise Value is ₹1,483 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vaidyane Ayurved Laboratories's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was ₹178 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) has a EV-to-EBITDA of 8.34 as of Sep. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vaidyane Ayurved Laboratories. This is 60% below median its historical median of 20.68. Over the past decade, Vaidyane Ayurved Laboratories' EV-to-EBITDA has ranged from 5.43 to 63.55. According to the industry distribution chart, Vaidyane Ayurved Laboratories ranks #219 out of 726 companies in the Drug Manufacturers industry, placing it in the top 30.2%.
Is Vaidyane Ayurved Laboratories' EV-to-EBITDA too high?
Vaidyane Ayurved Laboratories' current EV-to-EBITDA of 8.34 is 60% below median its 10-year median of 20.68. Over the past 10 years, this metric has ranged from a low of 5.43 to a high of 63.55. The Drug Manufacturers industry median EV-to-EBITDA is 13.55. Vaidyane Ayurved Laboratories' value of 8.34 is 38.5% below this industry median. Based on the distribution chart, Vaidyane Ayurved Laboratories ranks #219 out of 726 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vaidyane Ayurved Laboratories has a GF Score™ of 77/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vaidyane Ayurved Laboratories' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vaidyane Ayurved Laboratories ranks #219 out of 726 companies for EV-to-EBITDA. This puts Vaidyane Ayurved Laboratories in the upper half of its industry. The industry median EV-to-EBITDA is 13.55. Vaidyane Ayurved Laboratories' value of 8.34 is 38.5% below this benchmark. Historically, Vaidyane Ayurved Laboratories' own EV-to-EBITDA has ranged from 5.43 to 63.55 over the past decade. While the company's 10-year median is 20.68 vs. the industry median of 13.55, Vaidyane Ayurved Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.55, based on 726 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vaidyane Ayurved Laboratories's current EV-to-EBITDA of 8.34 is 38.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Vaidyane Ayurved Laboratories. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vaidyane Ayurved Laboratories's current EV-to-EBITDA is 8.34, which is 60% below median its own 10-year median of 20.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vaidyane Ayurved Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) is currently considered Possible Value Trap. The stock's GF Value™ is ₹228.29, compared to a current price of ₹160.50 — trading 29.7% below its estimated fair value. The current EV-to-EBITDA is 8.34, which is 60% below median its 10-year median of 20.68 and 38.5% below the Drug Manufacturers industry median of 13.55. Vaidyane Ayurved Laboratories' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG), the current EV-to-EBITDA is 8.34 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vaidyane Ayurved Laboratories (NSE:MADHAVBAUG) Overvalued in 2026?
Based on GuruFocus' analysis, Vaidyane Ayurved Laboratories stock appears to be undervalued.
The current stock price of ₹160.50 is trading 29.7% below its estimated GF Value™ of ₹228.29.
GuruFocus considers Vaidyane Ayurved Laboratories to be Possible Value Trap.
Key valuation signals for NSE:MADHAVBAUG:
EV-to-EBITDA: 8.34 (60% below median its 10-year median of 20.68)
GF Value™: ₹228.29 vs. price of ₹160.50 (29.7% below fair value)
Industry Position: 38.5% below the Drug Manufacturers median (#219 of 726)
No single metric tells the full story. See the NSE:MADHAVBAUG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vaidya Sane Ayurved Laboratories Ltd is a medical service institution. The company engaged in research and development in Ayurvedic Medicines and the sale of Ayurvedic medicines & products through its various franchises and own clinics. The Company is also engaged in providing Ayurved medical professional services across its various clinics, including panchkarma and other Ayurvedic treatments through the running of an Ayurvedic Hospital. The company mainly offers treatment for health disease reversal, diabetes reversal, BP management, obesity management, and knee pain relief. The company's business is divided into three segments, i.e., Hospital Activity, Sale of Product, and Common. It derives maximum revenue from the sale of Products.
77GF Score
Get the complete analysis for NSE:MADHAVBAUG
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MADHAVBAUG has been successfully added to your 
